|
業務類別
|
Biotechnology |
|
業務概覽
|
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate. |
| 公司地址
| 22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210 |
| 電話號碼
| +1 929 274-7510 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.akaritx.com |
| 員工數量
| 9 |
| Mr. Kameel D. Farag |
Interim Chief Financial Officer |
-- |
23/10/2025 |
| Mr. Abizer Gaslightwala |
Director, Chief Executive Officer and President |
-- |
20/03/2025 |
|
|
| Mr. Robert B. Bazemore, Jr |
Independent Director |
06/06/2025 |
| Mr. Sandip I. Patel |
Independent Director |
06/06/2025 |
| Mr. James R. Neal, M.B.A.,M.S. |
Independent Director |
06/06/2025 |
| Dr. Hoyoung Huh,M.D.,PhD |
Chairman of the Board |
06/06/2025 |
| Dr. Raymond Prudo-Chlebosz, M.D. |
Independent Director |
06/06/2025 |
| Dr. Samir R. Patel, M.D. |
Director |
20/03/2025 |
| Mr. Abizer Gaslightwala |
Director, Chief Executive Officer and President |
20/03/2025 |
|
|
|
|
